ALMB-0168

Small molecule

AAlaMab Therapeutics (Shanghai) Inc.

ALMB-0168 is one of 50 small molecule programs targeting Osteosarcoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaActive, not recruiting

OsteosarcomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Osteosarcoma

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

17 2

Ifex

BBaxter Healthcare Corporation

Phase 3

18 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

17 4

Vepesid

AAvyxa

Phase 3

12 5

Adriamycin

GGynecologic Oncology Group

Phase 3

10 6

PEG-Intron

Merck & Co.

Phase 3

1 7

Adriamycin

Pfizer

Phase 2

6 8

Standard Chemotherapy

Roche

Phase 3

1 9

Cabometyx

Bristol-Myers Squibb

Phase 2

3 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Solid Tumor

NCT06416358

Clinical

Trials by Indication[1]

Osteosarcoma1 trial

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Unknown status·AAlaMab Therapeutics (Shanghai) Inc.·Phase 1/2·NCT04886765·238 enrolled

Solid Tumor1 trial

A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

Not yet recruiting·AAlaMab Therapeutics (Shanghai) Inc.·Phase 2·NCT06416358·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALMB-0168. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALMB-0168 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALMB-0168. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AlaMab Therapeutics (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAlaMab Therapeutics (Shanghai) Inc.

ALMB-0168

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Osteosarcoma1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News